Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: A preliminary study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 2, 2006, Pages 286-291

  Yasui Furukori, Norio ^a   Saito, Manabu ^a   Nakagami, Taku ^a   Kaneda, Ayako ^a   Tateishi, Tomonori ^a   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Blood brain barrier; Bromperidol; C3435T; MDR1

Indexed keywords

ADENINE; BROMPERIDOL; GUANINE; THREONINE;

ACCOMMODATION PARALYSIS; ADULT; AGED; AKINESIA; ANXIETY; ARTICLE; ASTHENIA; AUTONOMIC DYSFUNCTION; BLOOD BRAIN BARRIER; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; C3435T GENE; CLINICAL ARTICLE; COGNITION; CONSTIPATION; CONTROLLED STUDY; DEFENSE MECHANISM; DEPRESSION; DIZZINESS; DNA POLYMORPHISM; DYSTONIA; EXCITEMENT; EXTRAPYRAMIDAL SYNDROME; FEMALE; G2677T/A GENE; GENE; GENOTYPE; HEART PALPITATION; HUMAN; HYPERKINESIA; HYPOKINESIA; MALE; MEMORY DISORDER; MENTAL DISEASE; MICTURITION DISORDER; MULTIDRUG RESISTANCE 1 GENE; MULTIPLE REGRESSION; MUSCLE RIGIDITY; NEGATIVE SYNDROME; POLYMERASE CHAIN REACTION; POSITIVE SYNDROME; SALIVATION DISORDER; SCHIZOPHRENIA; SCORING SYSTEM; SOMNOLENCE; TREATMENT RESPONSE; TREMOR;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; GENES, MDR; GENOTYPE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 33344477866     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.06.019     Document Type: Article

References (39)

1. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, and M.M. Gottesman Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu. Rev. Pharmacol. Toxicol. 39 1999 361 398
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders Fourth edition, Revised 1994 American Psychiatric Association Washington DC
3. P. Bech, M. Kastrup, and O.J. Rafaelsen Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes Acta Psychiatr. Scand. 73 Suppl. 326 1986 1S 37S
4. L.Z. Benet, T. Izumi, Y. Zhang, J.A. Silverman, and V.J. Wacher Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery Control. Release 62 1999 25 31
5. D.W. Boulton, C.L. DeVane, H.L. Liston, and J.S. Markowitz In vitro P-glycoprotein affinity for atypical and conventional antipsychotics Life Sci. 71 2002 163 169
6. C. Cordon-Cardo, J.P. O'Brien, D. Casals, L. Rittman-Grauer, J.L. Biedler, M.R. Melamed, and J.R. Bertino Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites Proc. Natl. Acad. Sci. U. S. A. 86 1989 695 698
7. E.L. Denijs Clinical evaluation of bromperidol versus haloperidol in psychiatric patients Int. Pharmacopsychiatry 15 1980 309 317
8. A.C. Egnell, B. Houston, and S. Boyer In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine J. Pharmacol. Exp. Ther. 305 2003 1251 1262
9. H. Furukori, T. Kondo, N. Yasui, K. Otani, N. Tokinaga, U. Nagashima, S. Kaneko, and Y. Inoue Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients Psychopharmacology 145 1999 189 192
10. S. Hoffmeyer, O. Burk, O. von Richter, H.P. Arnold, J. Brockmoller, A. Johne, I. Cascorbi, T. Gerloff, I. Roots, M. Eichelbaum, and U. Brinkmann Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc. Natl. Acad. Sci. U. S. A. 97 2000 3473 3478
11. N. Iida, K. Takara, N. Ohmoto, T. Nakamura, T. Kimura, A. Wada, M. Hirai, T. Sakaeda, and K. Okumura Reversal effects of antifungal drugs on multidrug resistance in MDR1-overexpressing HeLa cells Biol. Pharm. Bull. 24 2001 1032 1036
12. N. Isoherranen, K.L. Kunze, K.E. Allen, W.L. Nelson, and K.E. Thummel Role of itraconazole metabolites in CYP3A4 inhibition Drug Metab. Dispos. 32 2004 1121 1131
13. C.S. Karyekar, N.D. Eddington, T.S. Garimella, P.O. Gubbins, and T.C. Dowling Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model Pharmacotherapy 23 2003 436 442
14. A. Lazarowski, M. Massaro, A. Schteinschnaider, S. Intruvini, G. Sevlever, and A. Rabinowicz Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy Ther. Drug Monit. 26 2004 44 46
15. J.P. Lindenmayer, R. Bernstein-Hyman, S. Grochowski, and N. Bark Psychopathology of schizophrenia: initial validation of a 5-factor model Psychopathology 28 1995 22 31
16. O. Lingjaerde, U.G. Ahlfors, P. Bech, S.J. Dencker, and K. Elgen The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients Acta Psychiatr. Scand. 334 1987 1 100
17. M. Malfroid, L. Hens, P. Roosen, and R. Dom Double-blind evaluation of bromperidol versus haloperidol treatment in chronic patients Acta Psychiatr. Belg. 78 1987 147 154
18. C.J. Niemegeers, P.M. Laduron, and P.A. Janssen Pharmacology and biochemistry of bromperidol Acta Psychiatr. Belg. 78 1987 37 50
19. M.S. Ogg, T.J. Gray, and G.G. Gibson Development of an in vitro reporter gene assay to assess xenobiotic induction of the human CYP3A4 gene Eur. J. Drug Metab. Pharmacokinet. 22 1997 311 313
20. K. Otani, M. Ishida, N. Yasui, T. Kondo, K. Mihara, A. Suzuki, H. Furukori, S. Kaneko, and Y. Inoue Interaction between carbamazepine and bromperidol Eur. J. Clin. Pharmacol. 52 1997 219 222
21. J. Patel, and A.K. Mitra Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs Pharmacogenomics 2 2001 401 415
22. W. Poldinger, E. Bures, and H. Haage Double-blind study with two butyrophnone derivatives: bromperidol versus haloperidol Int. Pharmacopsychiatry 12 1977 184 192
23. V.V. Rao, J.L. Dahlheimer, M.E. Bardgett, A.Z. Snyder, R.A. Finch, A.C. Sartorelli, and D. Piwnica-Worms Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier Proc. Natl. Acad. Sci. U. S. A. 96 1999 3900 3905
24. R.L. Roberts, P.R. Joyce, R.T. Mulder, E.J. Begg, and M.A. Kennedy A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression Pharmacogenomics J. 2 2002 191 196
25. S. Sato, T. Someya, O. Shioiri, T. Koitabashi, and Y. Inoue Involvement of CYP3A4 in the metabolism of bromperidol in vitro Pharmacol. Toxicol. 86 2000 145 148
26. A. Schotte, P. Bonaventure, P.F.M. Janssen, and J.E. Leysen In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotic hitherto used Jpn. J. Pharmacol. 69 1995 399 412
27. W. Siegmund, K. Ludwig, T. Giessmann, P. Dazert, E. Schroeder, B. Sperker, R. Warzok, H.K. Kroemer, and I. Cascorbi The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol Clin. Pharmacol. Ther. 72 2002 572 583
28. 2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients Pharmacogenetics 10 2000 335 341
29. A. Suzuki, T. Kondo, K. Otani, K. Mihara, N. Yasui-Furukori, A. Sano, K. Koshiro, and S. Kaneko Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome Am. J. Psychiatry 158 2001 1714 1716
30. 2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients Pharmacogenetics 11 2001 545 550
31. M. Tanabe, I. Ieiri, N. Nagata, K. Inoue, S. Ito, Y. Kanamori, M. Takahashi, Y. Kurata, J. Kigawa, S. Higuchi, N. Terakawa, and K. Otsubo Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene J. Pharmacol. Exp. Ther. 297 2001 1137 1143
32. T. Tateishi, M. Watanabe, T. Kumai, M. Tanaka, H. Moriya, S. Yamaguchi, T. Satoh, and S. Kobayashi CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes Life Sci. 67 2000 2913 2920
33. F. Thiebaut, T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan, and M.C. Willingham Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc. Natl. Acad. Sci. U. S. A. 84 1987 7735 7738
34. J.I. Tracy, C. Monaco, T. Giovannetti, G. Abraham, and R.C. Josiassen Anticholinergicity and cognitive processing in chronic schizophrenia Biol. Psychol. 56 2001 1 22
35. L.L. von Moltke, D.J. Greenblatt, J. Schmider, S.X. Duan, C.E. Wright, J.S. Harmatz, and R.I. Shader Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents J. Clin. Pharmacol. 36 1996 783 791
36. F.A. Wong, C.P. Bateman, C.J. Shaw, and J.E. Patrick Biotransformation of bromperidol in rat, dog, and man Drug Metab. Dispos. 11 1983 301 307
37. B. Woggon Effects and side-effects of bromperidol in comparison with other antipsychotic drugs Acta Psychiatr. Belg. 78 1978 155 172
38. N. Yasui-Furukori, Y. Inoue, M. Chiba, and T. Tateishi Simultaneous determination of haloperidol and bromperidol and their reduced metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 805 2004 175 180
39. N. Yasui-Furukori, K. Mihara, T. Takahata, A. Suzuki, T. Nakagami, R. De Vries, T. Tateishi, T. Kondo, and S. Kaneko Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes Br. J. Clin. Pharmacol. 57 2004 569 575